ArticleScientific reports2025
The protective role of nuclear Heme oxygenase-1 in blood-spinal cord barrier after hypoxia in vitro.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Spinal cord injury (SCI), which results in severe lower-limb motor dysfunction, is a neurological disorder that damages the central nervous system. Disruption of the blood-spinal cord barrier (BSCB) results in secondary injury and neuronal apoptosis. Thus, this study aimed to investigate the effect of nuclear heme oxygenase-1 (HO-1) on BSCB after hypoxia in an in vitro model and to identify the potential regulatory mechanism of nuclear HO-1 (nHO-1) in BSCB. In an in vitro hypoxia model, nHO-1 treatment attenuated BSCB permeability. In addition, western blot analysis indicated that the expression levels of tight junction-associated proteins (ZO-1, occludin) and adherens junction-associated proteins (VE-cadherin) increased after treatment with nHO-1. Reverse transcription quantitative PCR assay showed that the mRNA levels of these proteins were remarkable in cells overexpressing nHO-1. The immunofluorescence staining of ZO-1 showed a similar trend. Our data indicated that nHO-1 decreased the number of TUNEL-positive cells. Therefore, nHO-1 could decrease the permeability of the BSCB by promoting the protein expression levels of ZO-1, occludin, and VE-cadherin and by reducing the apoptosis of spinal cord microvascular endothelial cells. Our study provides new insights into the molecular mechanism by which nHO-1 regulates BSCB after SCI, demonstrating that nHO-1 may be a viable target for the treatment of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.